NasdaqGS:VTRSPharmaceuticals
Viatris (VTRS) Could Be 59% Undervalued As Cash Flow And Pipeline Draw Focus
Recent analyst coverage has put Viatris (VTRS) in the spotlight as a value stock, with attention on its cash generation, late stage pipeline, and recent fixed income offerings that add another layer to the investment story.
See our latest analysis for Viatris.
Viatris has seen momentum build over 2026, with a 27.85% year to date share price return and a 22.07% 90 day share price return. The 1 year total shareholder return of 81.56% reflects how recent fixed income offerings and pipeline...